Vivimed Labs bags approval for 3 products of its Hyderabad manufacturing site; Stock ends 15.5% up

On Sensex, Vivimed Labs closed at Rs19.75 per piece up by 15.5%.

Apr 16, 2021 04:04 IST India Infoline News Service

Vivimed Labs announced on Friday that the company has received approvals for 3 products from its state of the art manufacturing site in Hyderabad, which is PICS & Health Canada approved site.

Ramesh Krishnamurthy, CEO of Vivimed Labs Ltd said, "These 3 approvals are testimony to high-quality teamwork of Vivimed 's end to end team. Branded exports are the strategic thrust of 'New and Vibrant Vivimed'. The approvals are testimony to Vivimed 's growth strategy"

These three products are:

Bilastine tablets 20mg under brand name FLUSTIN:

Bilastine is a second-generation antihistamine (a selective histamine H I receptor antagonist). It is used in the treatment of allergic Rhinoconjunctivitis and Urticaria (hives).

Ornidazole and Otloxacin tablets under brand name ORZOLE COMBI:

Ornidazole SOOmg + Ofloxacin 200mg tablets are used in the treatment of bacterial & parasitic infections. It is used to treat gastrointestinal infections such as acute diarrhoea or dysentery, gynaecological infections, lung infections and urinary infections.

Paracetamol 12Smg/Sml and Chlorpheniramine Maleate Syrup 2mg/Sml 100mi under brand name FEBRIL:

Paracetamol, also known as acetaminophen, is a medication used to treat fever and mild to moderate pain.

Chlorpheniramine Maleate is an antihistamine used to treat the symptoms of allergic conditions such as allergic rhinitis.

Menthol is a topical analgesic. It works by temporarily relieving minor pain.

On Sensex, Vivimed Labs closed at Rs19.75 per piece up by 15.5%.

Related Story

Open Free Demat Account (Rs699)